0PT.F Prothena Corporation plc

Healthcare Biotechnology Frankfurt Exchange
7.62 EUR
Close of Nov 11, 2026
6.73 9.76
Market cap
EUR 391M
P/E
-
P/B
1.64x
ROE
-1.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0PT.F undervalued?

Graham number

The Graham number of Prothena Corporation plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Prothena Corporation plc fundamental analysis

No fundamental analysis for Prothena Corporation plc yet.

Prothena Corporation plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial fo…

Full company profile